On December 24, Guangdong Boma Medical Technology Co., Ltd. (Boma Medical) announced that its IPO application for the ChiNext board of the Shenzhen Stock Exchange has been accepted. China International Capital Corporation Limited (CICC) serves as its sponsor, with plans to raise RMB 1.7 billion.
According to the prospectus, Boma Medical specializes in the R&D, production, and global sales of high-performance vascular interventional medical devices. It is a leading provider of solutions for complex vascular disease interventions and ranks among the top domestic manufacturers in terms of production and sales volume for vascular interventional balloon catheters.
The company has developed a comprehensive product portfolio covering multiple therapeutic scenarios, with over 50 product series. Its offerings span key areas such as coronary intervention, peripheral intervention, neurointervention, hemodialysis access, and interventional accessories. Core product lines include general-purpose balloon catheters, functional balloon catheters, drug-coated balloon catheters, guidewires and catheters, thrombectomy devices, calcification treatment devices, and energy-based therapy devices, addressing diverse clinical needs for complex vascular interventions.
In R&D and production, Boma Medical emphasizes global resource integration and capacity assurance. It operates five R&D centers and laboratories worldwide to drive technological innovation and product development, along with four production bases ensuring large-scale, high-quality supply. Additionally, three international operation centers support global market expansion with efficient logistics and services.
The company’s products are sold in over 100 countries and regions, serving tens of thousands of hospitals and medical centers globally. With reliable product performance, systematic treatment solutions, and professional technical support, Boma Medical has established a strong brand presence in both domestic and international vascular interventional device markets.
As an innovation-driven, technology-leading, and globally scaled enterprise in complex vascular interventions, Boma Medical has maintained rapid growth since commercialization. From 2022 to 2024, its revenue grew at a CAGR of 48.98%, positioning it as a high-growth player in the global vascular intervention sector.
The company operates international hubs in China, Europe, and the U.S., supplemented by regional sales offices, serving clients through a network of over 200 overseas distributors and nearly 800 domestic partners. Its products are used in more than 10,000 hospitals and medical centers.
Boma Medical holds a leading position in the vascular interventional device market, particularly in balloon catheter technology and large-scale production. According to Frost & Sullivan, in 2024, it ranked fourth in China’s coronary balloon catheter market with a 9.6% share (No. 1 among domestic brands) and fifth in the peripheral balloon catheter segment with 4.7%.
The proposed IPO proceeds, approved by the board and shareholders in November and December 2025, will be allocated to core business initiatives. Net proceeds after issuance costs will fund prioritized projects.
Financially, the company reported revenues of approximately RMB 207 million, RMB 335 million, RMB 460 million, and RMB 303 million for 2022, 2023, 2024, and H1 2025, respectively. Net profits during the same periods were RMB -36.06 million, RMB 25.99 million, RMB 76.78 million, and RMB 35.65 million.
Comments